checkAd

     231  0 Kommentare FDA Approves Medtronic Micra AV, the World’s Smallest Pacemaker Which Can Now Treat AV Block - Seite 2

    Medtronic will begin training field personnel and physicians, and will activate a limited number of implanting centers in the coming weeks, with full launch anticipated later this spring.

    “Since revolutionizing medicine with the first battery-powered cardiac pacemakers, Medtronic has continued to develop pioneering pacing technologies, culminating in the first miniaturized, leadless pacing portfolio for physicians and their patients,” said Rob Kowal, M.D., Ph.D., chief medical officer, vice president of medical affairs in the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic. “The introduction of Micra AV reinvents our own innovation, bringing the many benefits of leadless pacemakers to more patients.”

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Medtronic Inc!
    Short
    88,90€
    Basispreis
    0,61
    Ask
    × 12,43
    Hebel
    Long
    74,91€
    Basispreis
    0,71
    Ask
    × 11,15
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    About the Micra Transcatheter Pacing System (TPS)
    Approved by the FDA in 2016, the Micra TPS is a leadless pacemaker option for patients who only require pacing in the right ventricle. Comparable in size to a large vitamin, Micra is less than one-tenth the size of traditional pacemakers yet delivers advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, the device is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device.

    Unlike traditional pacemakers, Micra does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are eliminated - as are any visible signs of the device.

    In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. Medtronic strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

    To view an animation of the Micra AV in use, click here. (with no-voice over, click here)

    About Medtronic
    Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

    Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

    -end-

     

     

    Ryan Mathre
    Public Relations
    +1-651-335-2338

    Ryan Weispfenning
    Investor Relations
    +1-763-505-4626

    Attachments

    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    FDA Approves Medtronic Micra AV, the World’s Smallest Pacemaker Which Can Now Treat AV Block - Seite 2 With FDA Approval, More Patients in the U.S. Are Now Candidates for a Leadless Pacing Option DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) -  Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval of …